These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25335843)

  • 1. Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies.
    Brady M; Tolley E
    BJOG; 2014 Oct; 121 Suppl 5():70-8. PubMed ID: 25335843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making the case for multipurpose prevention technologies: the socio-epidemiological rationale.
    Boonstra H; Barot S; Lusti-Narasimhan M
    BJOG; 2014 Oct; 121 Suppl 5():23-6. PubMed ID: 25335837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond HIV microbicides: multipurpose prevention technology products.
    Malcolm RK; Boyd P; McCoy CF; Murphy DJ
    BJOG; 2014 Oct; 121 Suppl 5():62-9. PubMed ID: 25335842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from reproductive health to inform multipurpose prevention technologies: don't reinvent the wheel.
    Brady M; Manning J
    Antiviral Res; 2013 Dec; 100 Suppl():S25-31. PubMed ID: 24188700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach.
    Young Holt B; Romano J; Manning J; Hemmerling A; Shields W; Vyda L; Lusti-Narasimhan M
    BJOG; 2014 Oct; 121 Suppl 5():3-8. PubMed ID: 25335832
    [No Abstract]   [Full Text] [Related]  

  • 6. Condoms: the multipurpose prevention technologies that already exist.
    Warren M
    BJOG; 2014 Oct; 121 Suppl 5():9-11. PubMed ID: 25335833
    [No Abstract]   [Full Text] [Related]  

  • 7. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
    Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
    J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
    [No Abstract]   [Full Text] [Related]  

  • 8. Prioritizing multipurpose prevention technology development and investments using a target product profile.
    Romano J; Manning J; Hemmerling A; McGrory E; Holt BY
    Antiviral Res; 2013 Dec; 100 Suppl():S32-8. PubMed ID: 24188707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multipurpose prevention technologies for reproductive and sexual health.
    Stone A
    Reprod Health Matters; 2014 Nov; 22(44):213-7. PubMed ID: 25555778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities in funding the development and introduction of multipurpose prevention technologies.
    Manning J; Brown G; Vogelsong K; Kildebeck M; Zwerski S; Blithe D
    BJOG; 2014 Oct; 121 Suppl 5():12-4. PubMed ID: 25335834
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention.
    Krovi SA; Johnson LM; Luecke E; Achilles SL; van der Straten A
    Adv Drug Deliv Rev; 2021 Sep; 176():113849. PubMed ID: 34186143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of multipurpose prevention technology product strategies: understanding the market in parallel with product development.
    Romano JW; Van Damme L; Hillier S
    BJOG; 2014 Oct; 121 Suppl 5():15-8. PubMed ID: 25335835
    [No Abstract]   [Full Text] [Related]  

  • 13. Policy implications for multipurpose prevention technologies service delivery.
    Rees H; Forbes A
    BJOG; 2014 Oct; 121 Suppl 5():19-22. PubMed ID: 25335836
    [No Abstract]   [Full Text] [Related]  

  • 14. Interest in multipurpose prevention of HIV and pregnancy: perspectives of women, men, health professionals and community stakeholders in two vaginal gel studies in southern Africa.
    Woodsong C; Musara P; Chandipwisa A; Montgomery E; Alleman P; Chirenje M; Chipato T; Martinson F; Hoffman I
    BJOG; 2014 Oct; 121 Suppl 5():45-52. PubMed ID: 25335840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.
    Young Holt B; Dellplain L; Creinin MD; Peine KJ; Romano J; Hemmerling A
    Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):326-334. PubMed ID: 30247084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal multipurpose prevention technologies: promising approaches for enhancing women's sexual and reproductive health.
    Fernandes T; Baxi K; Sawarkar S; Sarmento B; das Neves J
    Expert Opin Drug Deliv; 2020 Mar; 17(3):379-393. PubMed ID: 32036727
    [No Abstract]   [Full Text] [Related]  

  • 17. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
    Woodsong C; Holt JD
    Adv Drug Deliv Rev; 2015 Sep; 92():146-54. PubMed ID: 25703190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexually transmitted infections and women's sexual and reproductive health.
    Gottlieb SL; Newman LM; Amin A; Temmerman M; Broutet N
    Int J Gynaecol Obstet; 2013 Dec; 123(3):183-4. PubMed ID: 24144238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contraceptives, HIV, and other sexually transmitted diseases].
    Vandale-Toney S; Conde-González CJ
    Ginecol Obstet Mex; 1995 Jan; 63():40-5. PubMed ID: 7896158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products.
    Schelar E; Polis CB; Essam T; Looker KJ; Bruni L; Chrisman CJ; Manning J
    Contraception; 2016 Jan; 93(1):32-43. PubMed ID: 26385588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.